Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study for the effect on blood glucose fluctuation by switching from DPP-4 inhibitor to SGLT2 inhibitor or to DPP-4 inhibitor/SGLT2 inhibitor combination tablet in patients with type 2 diabetes. - multicenter, prospective, randomized, open-label, parallel group, comparison study -

Trial Profile

Study for the effect on blood glucose fluctuation by switching from DPP-4 inhibitor to SGLT2 inhibitor or to DPP-4 inhibitor/SGLT2 inhibitor combination tablet in patients with type 2 diabetes. - multicenter, prospective, randomized, open-label, parallel group, comparison study -

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 Nov 2018

At a glance

  • Drugs Canagliflozin (Primary) ; Canagliflozin/teneligliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Oct 2018 Status changed from recruiting to active, no longer recruiting.
    • 23 Feb 2018 Status changed from not yet recruiting to recruiting.
    • 30 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top